The pharmacokinetics of thiopentone were compared in nine control patients and 10 patients with chronic alcoholism (without signs of cirrhosis or hepatitis) undergoing orthopaedic or abdominal surgery under general anaesthesia. The mean (± SD) alcohol intake was 92 ± 14 litre of ethanol per year in the alcoholic patients and less than 10 litre yr"' in the controls. Thiopentone plasma concentrations were measured by high pressure liquid chromatography after the administration of a single bolus dose (5-9mgkg" 1 ). The plasma clearance of thiopentone was significantly increased from 3.7 ±0.9 ml min" 1 kg"' in the controls to 5.4 ± 2.2 ml min" 1 kg" 1 in the patients with chronic alcoholism. The volume of the central compartment and the total apparent volume of distribution were similar in both groups. The terminal elimination half-life was of 684 ± 168 min in the alcoholics and did not differ significantly from the value found in the controls (75O±212min).
The requirements for thiopentone are believed to be greater in patients with chronic alcoholism (Keilty, 1969) . Several factors have been implicated: first, cross tolerance between ethanol and barbiturates (Loftetal., 1982) ; second, an increase in the volume into which the anaesthetic distributes, as a result of vasodilatation (Sellers and Holloway, 1978) and, third, an increase in the hepatic rate of elimination as a result of enzyme induction by ethanol (Rubin and Lieber, 1968) . To test these two latter hypotheses, the pharmacokinetics of thiopentone were evaluated in patients with chronic alcoholism but in whom there was no evidence of hepatic insufficency.
PATIENTS AND METHODS
Ten patients with chronic alcoholism, aged between 40 and 70 yr (55yr±9, mean±SD) and weighing 44-85 kg (63 kg± 11) and nine control patients between the ages of 28 and 76yr (46yr±18) and weighing 53-83 kg (69 kg ±13) undergoing elective surgery, were studied. Informed consent was given by all patients and the project was approved by the research Committee of the Hospital. Chronic alcoholism was defined as the consumption of an equivalent of at least 45 litre of ethanol per year for at least 1 year. This alcohol intake corresponds to 1.25 litre of wine or 0.30 litre of spirit each day. In the control group, the individual ethanol consumption varied from zero to less than 10 litre yr"
1
. None of the patients with chronic alcoholism had clinical evidence of hepato-cellular damage. In order to establish further the diagnosis of alcoholism, serum 7-glutamyl transpeptidase activity (GGTA) and the mean erythrocyte corpuscular volume were measured. Other biological tests, including the prothrombin time, serum glutamic pyruvate transaminase (SGPT) concentration and the haematocrit were measured also, and are shown in table I.
All patients underwent abdominal or orthopaedic surgery. Premedication consisted of atropine 0.5 mg i.m. and diazepam 10 mg by mouth given 45 min before the induction of anaesthesia. A single bolus of thiopentone 5.4-6.7mgkg" 1 (6.1mgkg" 1 ±0.3) in the alcoholic group, and of 5.0-8.3mgkg" 1 (6.3mgkg"'± 1.3) in the control patients was administered. Suxamethonium 0.8mgkg" 1 was given to facilitate tracheal intubation and general anaesthesia was maintained with 60% nitrous oxide in oxygen plus repeated doses of fentanyl. Pancuronium was administered when further neuromuscular blockade was required. Before the induction of anaesthesia, a catheter was inserted to a forearm vein and blood samples collected in heparinized plastic tubes at 0, 5, 10,15, 30, 45, 60 and 90 min, and at 2, 4, 8, 12, 16, 20, 24 and 48 h after the administration of thiopentone. Plasma was separated immediately and kept frozen at -18°C until analysis by high pressure liquid chromatography (Salvadori et al., 1981 method was 25ngml~1. The concentration-time curve for thiopentone was fitted, using a non-linear regression program (Gomeni and Gomeni, 1978) to two-and three-compartment pharmacokinetic models. Values were weighted by the inverse-square of the serum concentration. We determined the following variables: elimination half-life (Tfi, volume of the Central compartment (Vi), steady state volume of distribution (V*). Clearance (CO was determined by dividing the dose by the area under the curve as measured by the linear trapezoidal rule. Statistical differences between the data obtained in the individuals with chronic alcoholism and in the controls patients were analysed by the two-tailed non-parametric Mann-Whitney U test, with P< 0.05 being taken as the minimum level of statistical significance.
RESULTS
The clinical characteristics of the alcoholic patients are shown in table I, and their liver function tests in table II. The evolution of the mean plasma concentration v. time is displayed in figure 1 (for both groups). The plasma concentration curve was either biexponential or three-exponential in all patients. Individual pharmacokinetic parameters are listed in table III. No significant differences were observed in the volume of the central compartment, or in the total apparent volume of distribution. The plasma clearance was increased significantly from 3.7 ±0.9 ml min" 1 kg" 1 in the controls to 5.4±2.2 mlmin" 1 kg" 1 in the alcoholic group. The elimination half-life remained unchanged in the patients with chronic alcoholism. 
DISCUSSION
The patients with chronic alcoholism had no evidence of hepato-cellular failure. Prothrombin time and albumin plasma concentration, which are considered relatively good tests of hepatic function, were within normal limits in all patients. The increase in GGTA and the increase in SGPT observed in some patients probably correspond to some degree of steatosis or cell necrosis. In this study, the dose of thiopentone was similar in the two groups of patients. The only change observed in the pharmacokinetics of thiopentone was an increase in plasma clearance. This change is probably explained by a stimulation of the hepatic monooxygenase system by chronic ethanol consumption (Rubin and Lieber, 1968) .
Thiopentone is a drug with a low hepatic extraction coefficient (Morgan et al., 1981) and changes in drug metabolizing capacity will influence its plasma clearance. Despite the increase in plasma clearance, there was no significant change in the elimination half-life in the alcoholic patients. Thiopentone has a very large volume of distribution owing to its lipid solubility. For this category of drugs, changes in plasma clearance will affect the elimination half-life very little. In previous studies in patients with cirrhosis, we were unable to demonstrate changes in the elimination half-life of thiopentone (Pandele et al., 1983) or of fentanyl (Haberer et al., 1982) . These two drugs are highly lipid-soluble and their profile of elimination is influenced mainly by redistribution from deep tissue depots. The duration of effect and the dose requirement of thiopentone are more likely to be influenced by change in distribution processes than by capacity for drug elimination. No change in the central volume of distribution was observed in the alcoholic patients, suggesting that there is no pharmacokinetic explanation for the need for a higher initial dose in patients with chronic alcoholism.
Thiopentone (like many acidic compounds) is bound extensively to albumin. Several factors may alter the protein binding of this drug in alcoholics and therefore modify the pharmacological effect which is related to the free fraction (Becker, 1978) . An increase in the free fraction of thiopentone was observed in patients with alcoholic cirrhosis (Pandele et al., 1983 ). An increase in the free fatty acids in alcoholic patients may displace acidic drugs from their binding to albumin (Sandor et al., 1983) . In the present study, the plasma protein binding of thiopentone was not studied. However, if alcoholism influences the protein binding of thiopentone, an increase in the free fraction could be expected. However, this change would cause an increase in the sensitivity to thiopentone-which appears unlikely in alcoholics.
Thus, the clinical impression for an increase in the thiopentone dose requirement in alcoholics has no pharmacokinetic support. Cross tolerance between thiopentone and ethanol appears to be a likely explanation. Se compare la farmacocinetica de la tiopentona en nuevc pacientes de control y 10 pacientes con alcoholismo cronico (sin senates de drr6sis o hepatitis) sometidos a operaciones quirurgicas abdominales u ortopedicas bajo anestetia general. La absoqxion media de alcohol (± SD) era de 92 ± 14 litros de etanol por afjo en los pacientes alcoholicos y menos de 10 litros ano" 1 en los controles. Semidieron las concentracionesde tiopentona en el plasma mediante cromatograf ia liquida de alta presi6n despues de la administracion de una dosis de bolo unica (5-9mgkg~1). La eliminarion del plasma de la tiopentona aumento de mantra significante de 3,7±0,9mlmin~ kg" 1 en los controles hasta 5,4 ±2^ ml min~1 kg" enlospacientesconalcoholismocr6nico. F1 volumen del compartimiento central y d volumen aparente total de distribucion eran similares en ambos grupos. La mediavida de eliminacion terminal era de 684 ±168 min en los alcoholicos y no diferia mayormente H^l valor encontrado en los controles (7 50 ± 212 min).
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